Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Open accessThe DOI matches its Crossref record; 427 of the 427 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant, primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic heterogeneity, and protection by the blood brain barrier (BBB) have posed great treatment challenges. The standard treatment for GBMs is surgical resection followed by chemoradiotherapy. The robust DNA repair and self-renewing capabilities of glioblastoma cells and glioma initiating cells (GICs), respectively, promote resistance against all current treatment modalities. Thus, durable GBM management will require the invention of innovative treatment strategies. In this review, we will describe biological and molecular targets for GBM therapy, the current status of pharmacologic therapy, prominent mechanisms of resistance, and new treatment approaches. To date, medical imaging is primarily used to determine the location, size and macroscopic morphology of GBM before, during, and after therapy. In the future, molecular and cellular imaging approaches will more dynamically monitor the expression of molecular targets and/or immune responses in the tumor, thereby enabling more immediate adaptation of tumor-tailored, targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 427
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature11903 · Cited by 167
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 166
Hanna, C. R., Kurian, K. M., Williams, K., Watts, C., Jackson, A., Carruthers, R., Strathdee, K. E., Cruickshank, G. S., Dunn, L., Erridge, S., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa104 · Cited by 165
Ceresoli, G. L., Aerts, J. G., Dziadziuszko, R., Ramlau, R., Cedres, S., van Meerbeeck, J. P., Mencoboni, M., Planchard, D., Chella, A., Crinò, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30532-7 · Cited by 164
Targeted Nanotechnology in Glioblastoma Multiforme
Glaser, T., Han, I., Wu, L., & Zeng, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00166 · Cited by 164
Chinnaiyan, P., Won, M., Wen, P. Y., Rojiani, A. M., Werner‐Wasik, M., Shih, H. A., Ashby, L. S., Yu, H.-H. M., Stieber, V. W., Malone, S. C., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox209 · Cited by 164
Lopez-Bertoni, H., Kozielski, K. L., Rui, Y., Lal, B., Vaughan, H., Wilson, D. R., Mihelson, N., Eberhart, C. G., Laterra, J., & Green, J. J. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00390 · Cited by 164
Galanis, E., Anderson, S. K., Lafky, J. M., Uhm, J. H., Giannini, C., Kumar, S. K., Kimlinger, T. K., Northfelt, D. W., Flynn, P. J., Jaeckle, K. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0708 · Cited by 162
Fidoamore, A., Cristiano, L., Antonosante, A., d’Angelo, M., Di Giacomo, E., Astarita, C., Giordano, A., Ippoliti, R., Benedetti, E., & Cimini, A. (2016) · Stem Cells International · doi:10.1155/2016/6809105 · Cited by 162
Miller, S. E., Tummers, W. S., Teraphongphom, N., van den Berg, N. S., Hasan, A., Ertsey, R. D., Nagpal, S., Recht, L. D., Plowey, E. D., Vogel, H., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2854-0 · Cited by 160
Anti-angiogenic therapy for high-grade glioma
Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J., & Khasraw, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008218.pub4 · Cited by 159
Cerullo, V., Diaconu, I., Kangasniemi, L., Rajecki, M., Escutenaire, S., Koski, A., Romano, V., Rouvinen, N., Tuuminen, T., Laasonen, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.113 · Cited by 159
Tobacco Smoke Induces Polycomb-Mediated Repression of Dickkopf-1 in Lung Cancer Cells
Hussain, M., Rao, M., Humphries, A. E., Hong, J. A., Liu, F., Yang, M., Caragacianu, D., & Schrump, D. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2807 · Cited by 159
Wick, W., Gorlia, T., Bady, P., Platten, M., van den Bent, M. J., Taphoorn, M. J. B., Steuve, J., Brandes, A. A., Hamou, M.-F., Wick, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3153 · Cited by 159
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Kaplan, A. R., Gueble, S. E., Liu, Y., Oeck, S., Kim, H., Yun, Z., & Glazer, P. M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4508 · Cited by 158
Wick, W., Dettmer, S., Berberich, A., Keßler, T., Karapanagiotou‐Schenkel, I., Wick, A., Winkler, F., Pfaff, E., Brors, B., Debus, J., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy161 · Cited by 157
Glioblastoma, hypoxia and autophagy: a survival-prone ‘ménage-à-trois’
Jawhari, S., Ratinaud, M., & Verdier, M. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.318 · Cited by 153
Woensel, M. V., Mathivet, T., Wauthoz, N., Rosière, R., Garg, A. D., Agostinis, P., Mathieu, V., Robert Kiss, A., Lefranc, F., Boon, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01279-1 · Cited by 152
Geoerger, B., Kieran, M. W., Grupp, S. A., Perek, D., Clancy, J. S., Krygowski, M., Ananthakrishnan, R., Boni, J. P., Berkenblit, A., & Spunt, S. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.021 · Cited by 148
EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma
Choi, B. D., Archer, G. E., Mitchell, D. A., Heimberger, A. B., McLendon, R. E., Bigner, D. D., & Sampson, J. H. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00318.x · Cited by 148
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
Lassman, A. B., Pugh, S. L., Gilbert, M. R., Aldape, K. D., Geinoz, S., Beumer, J. H., Christner, S. M., Komaki, R., DeAngelis, L. M., Gaur, R., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov011 · Cited by 147
Cabrini, G., Fabbri, E., Nigro, C. L., Dechecchi, M. C., & Gambari, R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3026 · Cited by 146
Christians, A., Hartmann, C., Benner, A., Meyer, J., von Deimling, A., Weller, M., Wick, W., & Weiler, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033449 · Cited by 146
Kolenda, J., Jensen, S. S., Aaberg-Jessen, C., Christensen, K., Andersen, C., Brünner, N., & Kristensen, B. W. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0357-8 · Cited by 144
New insights into the mechanism of DNA mismatch repair
Reyes, G. X., Schmidt, T. T., Kolodner, R. D., & Hombauer, H. (2015) · Chromosoma · doi:10.1007/s00412-015-0514-0 · Cited by 143
Zhang, Q., & Liu, F. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2696-5 · Cited by 142
Hua, L., Wang, Z., Zhao, L., Mao, H., Wang, G., Zhang, K., Liu, X., Wu, D., Zheng, Y., Lu, J., et al. (2018) · Theranostics · doi:10.7150/thno.26225 · Cited by 140
O6-alkylguanine DNA lesions trigger apoptosis
Meikrantz, W. (1998) · Carcinogenesis · doi:10.1093/carcin/19.2.369 · Cited by 139
O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy
Verbeek, B., Southgate, T. D., Gilham, D. E., & Margison, G. P. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldm036 · Cited by 138
Bort, G., Lux, F., Dufort, S., Crémillieux, Y., Verry, C., & Tillement, O. (2020) · Theranostics · doi:10.7150/thno.37543 · Cited by 138
Tumor treating fields increases membrane permeability in glioblastoma cells
Chang, E., Patel, C. B., Pohling, C., Young, C., Song, J., Flores, T. A., Zeng, Y., Joubert, L.-M., Arami, H., Natarajan, A., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0130-x · Cited by 137
Self-citationPerez, O. D., Logg, C. R., Hiraoka, K., Diago, O. R., Burnett, R., Inagaki, A., Jolson, D., Amundson, K., Buckley, T., Lohse, D., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.83 · Cited by 137
Liu, H., Chen, L., Liu, J., Meng, H., Zhang, R., Ma, L., Wu, L., Yu, S., Shi, F., Li, Y., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.022 · Cited by 136
Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
Kailayangiri, S., Altvater, B., Wiebel, M., Jamitzky, S., & Rössig, C. (2020) · Cancers · doi:10.3390/cancers12051075 · Cited by 136
Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets
Codrici, E., Enciu, A., Popescu, I. D., Mihai, S., & Tănase, C. (2016) · Stem Cells International · doi:10.1155/2016/5728438 · Cited by 135
Uribe, D., Torres, Á., Rocha, J. D., Niechi, I., Oyarzun, C. E., Sobrevía, L., Martín, R. S., & Quezada, C. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.009 · Cited by 135
Reardon, D. A., Dresemann, G., Taillibert, S., Campone, M., van den Bent, M., Clement, P., Blomquist, E., Gordower, L., Schultz, H., Raizer, J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605411 · Cited by 133
Reardon, D. A., Vredenburgh, J. J., Desjardins, A., Peters, K., Gururangan, S., Sampson, J. H., Marcello, J., Herndon, J. E., McLendon, R. E., Janney, D., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0217-6 · Cited by 132
MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells
Talukdar, S., Pradhan, A. K., Bhoopathi, P., Shen, X., August, L. A., Windle, J. J., Sarkar, D., Furnari, F. B., Cavenee, W. K., Das, S. K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721650115 · Cited by 132
McFaline‐Figueroa, J. L., Braun, C. J., Stanciu, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3616 · Cited by 131
Hainsworth, J. D., Ervin, T. J., Friedman, E. K., Priego, V. M., Murphy, P. B., Clark, B. L., & Lamar, R. E. (2010) · Cancer · doi:10.1002/cncr.25275 · Cited by 131
Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer
Jin, N., Bi, A., Lan, X., Xu, J., Wang, X., Liu, Y., Wang, T., Tang, S., Zeng, H., Chen, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10427-2 · Cited by 131
Cho, S. S., Salinas, R. D., & Lee, J. Y. K. (2019) · Frontiers in Surgery · doi:10.3389/fsurg.2019.00011 · Cited by 130
Epigenetic Targeting of Glioblastoma
Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 129
Sousa, F., Dhaliwal, H. K., Gattacceca, F., Sarmento, B., & Amiji, M. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.033 · Cited by 128
Liu, C., Zhao, G., Liu, J., Ma, N., Chivukula, P., Perelman, L. A., Okada, K., Chen, Z., Gough, D., & Yu, L. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.08.013 · Cited by 127
Wen, P. Y., Drappatz, J., de Groot, J., Prados, M. D., Reardon, D. A., Schiff, D., Chamberlain, M. C., Mikkelsen, T., Desjardins, A., Holland, J. S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox154 · Cited by 127
Sevenich, L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00163 · Cited by 127
Nano-Therapies for Glioblastoma Treatment
Alphandéry, E. (2020) · Cancers · doi:10.3390/cancers12010242 · Cited by 126
Gerber, D. E., Grossman, S. A., Zeltzman, M., Parisi, M., & Kleinberg, L. R. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-024 · Cited by 124
Real‐Time Imaging of Brain Tumor for Image‐Guided Surgery
Hu, S., Kang, H., Baek, Y., Fakhri, G. E., Kuang, A., & Choi, H. S. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800066 · Cited by 124
Gomez-Zepeda, D., Taghi, M., Scherrmann, J.-M., Decleves, X., & Menet, M.-C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics12010020 · Cited by 124
Curley, C. T., Mead, B. P., Negrón, K., Kim, N., Garrison, W. J., Miller, G. W., Kingsmore, K. M., Thim, E. A., Song, J. S., Munson, J. M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay1344 · Cited by 124
Kurokawa, C., Iankov, I. D., Anderson, S. K., Aderca, I., Leontovich, A. A., Maurer, M. J., Oberg, A. L., Schroeder, M. A., Giannini, C., Greiner, S. M., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy033 · Cited by 122
Malatesta, M., Steinhauer, C., Mohammad, F., Pandey, D. P., Squatrito, M., & Helin, K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4660 · Cited by 119
Yang, J., Shi, Z., Liu, R., Wu, Y., & Zhang, X. (2020) · Theranostics · doi:10.7150/thno.40298 · Cited by 118
Self-citationNew trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
Westover, D., & Li, F. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0275-x · Cited by 116
Continuous daily sunitinib for recurrent glioblastoma
Kreisl, T. N., Smith, P., Sul, J., Salgado, C., IWAMOTO, F. M., Shih, J. H., & Fine, H. A. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0988-z · Cited by 113
DNA methylation and histone modifications as epigenetic regulation in prostate cancer
Nowacka‐Zawisza, M., & Wiśnik, E. (2017) · Oncology Reports · doi:10.3892/or.2017.5972 · Cited by 113
Razis, E. D., Selviaridis, P., Labropoulos, S., Norris, J. L., Zhu, M. J., Song, D. D., Kalebic, T., Torrens, M. J., Kalogera‐Fountzila, A., Karkavelas, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1867 · Cited by 110
Lassen, U., Mau‐Sørensen, M., Gaziel, T. B. B., Hasselbalch, B., & Poulsen, H. S. (2013) · PubMed · Cited by 110
Khan, A., Aqil, M., Imam, S. S., Ahad, A., Sultana, Y., Ali, A., & Khan, K. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.05.079 · Cited by 110
Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma
Grafals-Ruiz, N., Rios-Vicil, C. I., Lozada-Delgado, E. L., Quiñones-Díaz, B. I., Noriega-Rivera, R. A., Martínez-Zayas, G., Santana-Rivera, Y., Santiago-Sánchez, G. S., Valiyeva, F., & Vivas-Mejía, P. E. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s241055 · Cited by 110
PARP1 Inhibitors: Antitumor Drug Design
Malyuchenko, N. V., Kotova, E. Y., Kulaeva, O. I., Kirpichnikov, M. P., & Studitskiy, V. M. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-3-27-37 · Cited by 109
Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer
Mesrati, M. H., Behrooz, A. B., Abuhamad, A. Y., & Syahir, A. (2020) · Cells · doi:10.3390/cells9051236 · Cited by 108
Obstacles to Brain Tumor Therapy: Key ABC Transporters
Wijaya, J., Fukuda, Y., & Schuetz, J. D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122544 · Cited by 107
Gandhi, S., Meybodi, A. T., Belykh, E. G., Cavallo, C., Zhao, X., Syed, M. P., Moreira, L. B., Lawton, M. T., Nakaji, P., & Preul, M. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00620 · Cited by 107
Murty, S., Haile, S. T., Beinat, C., Aalipour, A., Alam, I. S., Murty, T., Shaffer, T. M., Patel, C. B., Graves, E. E., Mackall, C. L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1757360 · Cited by 106
Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
Mecca, C., Giambanco, I., Donato, R., & Arcuri, C. (2018) · Disease Markers · doi:10.1155/2018/9230479 · Cited by 105
l-Acetylcarnitine: A Mechanistically Distinctive and Potentially Rapid-Acting Antidepressant Drug
Chiechio, S., Canonico, P., & Grilli, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010011 · Cited by 104
Lesueur, P., Chevalier, F., El-Habr, E. A., Junier, M., Chneiweiss, H., Castéra, L., Müller, E., Stefan, D., & Saintigny, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-22022-4 · Cited by 104
The current state of immunotherapy for gliomas: an eye toward the future
Fecci, P. E., & Sampson, J. H. (2019) · Journal of neurosurgery · doi:10.3171/2019.5.jns181762 · Cited by 104
Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches
Huang, W., Chen, W., & Zhang, X. (2016) · Oncology Letters · doi:10.3892/ol.2016.4952 · Cited by 103
Kegelman, T. P., Wu, B., Das, S. K., Talukdar, S., Beckta, J. M., Hu, B., Emdad, L., Valerie, K. C., Sarkar, D., Furnari, F. B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616100114 · Cited by 103
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer
Gao, D., Herman, J. G., & Guo, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7949 · Cited by 102
Baxter, P. A., Su, J. M. F., Onar‐Thomas, A., Billups, C. A., Li, X., Poussaint, T. Y., Smith, E. R., Thompson, P., Adesina, A. M., Ansell, P. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa016 · Cited by 102
Avci, N. G., Pustchi, S. E., Akay, Y. M., Esquenazi, Y., Tandon, N., Zhu, J., & Akay, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-70392-5 · Cited by 101
Peereboom, D. M., Ahluwalia, M. S., Ye, X., Supko, J. G., Hilderbrand, S. L., Phuphanich, S., Nabors, L. B., Rosenfeld, M. R., Mikkelsen, T., & Grossman, S. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos322 · Cited by 100
Pompoš, A., Durante, M., & Choy, H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2646 · Cited by 100
Hainsworth, J. D., Shih, K. C., Shepard, G. C., Tillinghast, G. W., Brinker, B. T., & Spigel, D. R. (2012) · PubMed · Cited by 99
van den Anker, J. N., McCune, S., Annaert, P., Baer, G., Mulugeta, Y. A., Abdelrahman, R. A., Wu, K., Krudys, K. M., Fisher, J. W., Slikker, W., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070685 · Cited by 97
Clarke, M. J., Mulligan, E. A., Grogan, P. T., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Curtin, N. J., Lou, Z., Decker, P. A., Wu, W., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0854 · Cited by 95
Self-citationVEGF Manipulation in Glioblastoma.
Weathers, S.-P. S., & de Groot, J. (2015) · PubMed · Cited by 95
Münster, P. N., Mita, M. M., Mahipal, A., Nemunaitis, J. J., Massard, C., Mikkelsen, T., Cruz, C., Paz-Ares, L. G., Hidalgo, M. M., Rathkopf, D. E., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s208720 · Cited by 95
Bocangel, D., Sengupta, S., MITRA, S. P., & Bhakat, K. K. (2009) · PubMed · Cited by 94
Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy
Liu, H., Zhang, Y., Xie, Y., Cai, Y., Baiyang, L., Li, W. J., Zeng, L.-Y., Li, Y., & Yu, R. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s125286 · Cited by 94
Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment
Belhadj, Z., Zhan, C., Man, Y. M., Wei, X., Xie, C., Yan, Z., & Lu, W. (2017) · Oncotarget · doi:10.18632/oncotarget.17976 · Cited by 94
Cellular origin of glioblastoma and its implication in precision therapy
Yao, M., Li, S., Wu, X., Diao, S., Zhang, G., He, H., Bian, L., & Lu, Y. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.159 · Cited by 94
Wu, M., Lin, C.-L., Chiou, H., Yang, S., Lin, C., Liu, C., & Hsieh, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010010 · Cited by 92
Convection-Enhanced Delivery of Carboplatin PLGA Nanoparticles for the Treatment of Glioblastoma
Arshad, A., Yang, B., Bienemann, A. S., Barua, N. U., Wyatt, M. J., Woolley, M., Johnson, D. E., Edler, K. J., & Gill, S. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132266 · Cited by 91
Parrish, K. E., Cen, L., Murray, J., Calligaris, D., Kizilbash, S., Mittapalli, R. K., Carlson, B. L., Schroeder, M. A., Sludden, J., Boddy, A. V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0553 · Cited by 91
Finbloom, J. A., Aanei, I. L., Bernard, J. M. L., Klass, S. H., Elledge, S. K., Han, K., Ozawa, T., Nicolaides, T. P., Berger, M. S., & Francis, M. B. (2018) · Nanomaterials · doi:10.3390/nano8121007 · Cited by 91
Global Histone Modification Patterns as Prognostic Markers to Classify Glioma Patients
Liu, B.-L., Cheng, J., Zhang, X., Wang, R., Zhang, W., Lin, H., Xiao, X., Cai, S., Chen, X.-Y., & Cheng, H. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0454 · Cited by 90
Collaborative, B. T. T., Raizer, J. J., Giglio, P., Hu, J. L., Groves, M., Merrell, R. T., Conrad, C., Phuphanich, S., Puduvalli, V. K., Loghin, M. E., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1958-z · Cited by 90
Kizilbash, S. H., Gupta, S. K., Chang, K., Kawashima, R., Parrish, K. E., Carlson, B. L., Bakken, K. K., Mladek, A. C., Schroeder, M. A., Decker, P. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0365 · Cited by 90
MicroRNAs as biomarkers for human glioblastoma: progress and potential
Huang, S., Ali, N.-D., Zhong, L., & Shi, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.173 · Cited by 90
Evolution of Magnetic Hyperthermia for Glioblastoma Multiforme Therapy
Gupta, R., & Sharma, D. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00652 · Cited by 90
Xu, Y., Wu, H. C., Huang, J., Qian, W., Martinson, D. E., Ji, B., Li, Y., Wang, Y. A., Yang, L. P. H., & Mao, H. Z. (2020) · Theranostics · doi:10.7150/thno.39560 · Cited by 90
Image-guided Biopsy: What the Interventional Radiologist Needs to Know about PET/CT
Kobayashi, K., Bhargava, P., Raja, S., Nasseri, F., Al‐Balas, H., Smith, D. D., George, S., & Vij, M. S. (2012) · Radiographics · doi:10.1148/rg.325115159 · Cited by 89
Pandith, A. A., Qasim, I., Zahoor, W., Shah, P., Bhat, A. R., Sanadhya, D., Shah, Z. A., & Naykoo, N. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-25169-2 · Cited by 88
Metabolic Reprogramming in Mitochondria of Myeloid Cells
Zuo, H., & Wan, Y. (2019) · Cells · doi:10.3390/cells9010005 · Cited by 88
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma
Pan, E., Yu, D., Yue, B., Potthast, L., Chowdhary, S. A., Smith, P. S., & Chamberlain, M. C. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0943-z · Cited by 87
Brandes, A. A., Finocchiaro, G., Zagonel, V., Reni, M., Caserta, C., Fabi, A., Clavarezza, M., Maiello, E., Eoli, M., Lombardi, G., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now035 · Cited by 86
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
Schäfer, N., Gielen, G. H., Rauschenbach, L., Kebir, S., Till, A., Reinartz, R., Simon, M., Niehusmann, P., Kleinschnitz, C., Herrlinger, U., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1846-y · Cited by 86
Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide
Dico, A. L., Martelli, C., Diceglie, C., Lucignani, G., & Ottobrini, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00249 · Cited by 84
Gupta, S. K., Smith, E. J., Mladek, A. C., Tian, S., Decker, P. A., Kizilbash, S. H., Kitange, G. J., & Sarkaria, J. N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00670 · Cited by 84
Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells
Yong, S., Chung, J. Y., Song, Y., Kim, J., Ra, S., & Kim, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119401 · Cited by 84
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists
Burri, S. H., Gondi, V., Brown, P. D., & Mehta, M. P. (2017) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000395 · Cited by 83
Chang, K., Hsu, T., Hsu, C.-C., Tsai, S.-Y., Liu, J.-J., Chou, S.-W., Liu, M.-S., Liou, J., Ko, C., Chen, K., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.08.005 · Cited by 82
ABC transporters in CSCs membranes as a novel target for treating tumor relapse
Zinzi, L., Contino, M., Cantore, M., Capparelli, E., Leopoldo, M., & Colabufo, N. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00163 · Cited by 81
Bigner, D. D., Pitts, O. M., & Wikstrand, C. J. (1981) · Journal of neurosurgery · doi:10.3171/jns.1981.55.1.0032 · Cited by 81
Emerging circulating biomarkers in glioblastoma: promises and challenges
Touat, M., Durán-Peña, A., Alentorn, A., Lacroix, L., Massard, C., & Idbaïh, A. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1087315 · Cited by 81
Chiblak, S., Tang, Z., Lemke, D., Knoll, M., Đokić, I., Warta, R., Moustafa, M., Mier, W., Brons, S., Rapp, C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123837 · Cited by 81
Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
Garzón-Muvdi, T., Theodros, D., Luksik, A. S., Maxwell, R., Kim, E. S., Jackson, C. M., Belcaid, Z., Ganguly, S., Tyler, B., Brem, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25061 · Cited by 79
Ruiz-Garcia, H. J., Alvarado-Estrada, K., Schiapparelli, P. V., Quiñones‐Hinojosa, A., & Trifiletti, D. M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.558381 · Cited by 79
Regulation of histone methylation by noncoding RNAs
Joh, R. I., Palmieri, C. M., Hill, I. T., & Motamedi, M. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.06.006 · Cited by 78
Robins, H. I., Zhang, P., Gilbert, M. R., Chakravarti, A., de Groot, J., Grimm, S. A., Wang, F., Lieberman, F. S., Krauze, A. V., Trotti, A., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1966-z · Cited by 76
Wu, W. E., Wu, Y., Mayer, K., von Rosenstiel, C., Schecker, J., Baur, S., Würstle, S. M., Liesche‐Starnecker, F., Gempt, J., & Schlegel, J. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100748 · Cited by 76
Self-citationOhue, S., Kumon, Y., Nagato, S., et al. (2010) · Neurologia medico-chirurgica · doi:10.2176/nmc.50.291 · Cited by 75
Jang, E., Kim, E., Son, H. Y., Lim, E., Lee, H., Choi, Y., Park, K., Han, S., Suh, J., Huh, Y., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.036 · Cited by 75
Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity
Qian, J., & Rankin, E. B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_3 · Cited by 75
Galanis, E., Anderson, S. K., Twohy, E. L., Carrero, X. W., Dixon, J. G., Tran, D. D., Jeyapalan, S. A., Anderson, D. M., Kaufmann, T. J., Feathers, R. W., et al. (2019) · Cancer · doi:10.1002/cncr.32340 · Cited by 75
Kunwar, S., Sm, C., Prados, Berger, M. S., Sampson, J. H., Croteau, D. J., Sherman, J. W., Ay, G., Vs, S., Dul, J. L., et al. (2006) · PubMed · Cited by 74
Zhou, Y., Li, Y., Zhang, X., Chen, R., Chen, X., Tang, W., & Zhang, M. (2019) · BioMed Research International · doi:10.1155/2019/6581576 · Cited by 74
Self-citationHigh Expression of CD44 Predicts a Poor Prognosis in Glioblastomas
Si, D., Yin, F., Peng, J., & Zhang, G. (2020) · Cancer Management and Research · doi:10.2147/cmar.s233423 · Cited by 74
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
Syro, L. V., Rotondo, F., Camargo, M., Ortiz, L. D., Serna, C. A., & Kovács, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00318 · Cited by 73
Cloughesy, T. F., Drappatz, J., de Groot, J., Prados, M. D., Reardon, D. A., Schiff, D., Chamberlain, M. C., Mikkelsen, T., Desjardins, A., Ping, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox151 · Cited by 73
Chekhonin, V. P., Baklaushev, V. P., Yusubalieva, G. M., Belorusova, A. E., Gulyaev, M. V., Tsitrin, E. B., Grinenko, N. F., Gurina, O. I., & Pirogov, Y. A. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.05.011 · Cited by 72
Schebesch, K.-M., Brawanski, A. T., Hohenberger, C., & Höhne, J. (2016) · Turkish Neurosurgery · doi:10.5137/1019-5149.jtn.16952-16.0 · Cited by 72
The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review
Brahm, C. G., Linde, M. E. V., Enting, R. H., Schuur, M., Otten, R. H. J., Heymans, M. W., Verheul, H. M. W., & Walenkamp, A. (2020) · Cancers · doi:10.3390/cancers12030586 · Cited by 72
Yu, Z., Chen, Y., Wang, S., Li, P., Zhou, G., & Yuan, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.033 · Cited by 71
Chen, Y., Fang, R., Yue, C., Chang, G., Li, P., Guo, Q., Wang, J., Zhou, A., Zhang, S., Fuller, G. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1229 · Cited by 71
Fisher, D. G., & Price, R. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01348 · Cited by 70
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Zustovich, F., Landi, L. M., Lombardi, G., Porta, C., Galli, L., Fontana, A., AMOROSO, D., Galli, C., Andreuccetti, M., Falcone, A., et al. (2013) · PubMed · Cited by 69
Discovery of an Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B
Xie, C., Wang, Z., Su, Y., Wang, J., & Shen, W.-C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010021 · Cited by 69
Magnetic hyperthermia therapy in glioblastoma tumor on-a-Chip model
Mamani, J. B., Marinho, B. S., Rego, G. N. A., Nucci, M. P., Alvieri, F., dos Santos, R. S., Ferreira, J. V. M., Oliveira, F. A., & Gamarra, L. F. (2019) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2020ao4954 · Cited by 68
Manganese-Doped Magnetic Nanoclusters for Hyperthermia and Photothermal Glioblastoma Therapy
Gupta, R., & Sharma, D. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c00121 · Cited by 68
Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry
Luo, H., Hernandez, R., Hong, H., Graves, S. A., Yang, Y., England, C. G., Theuer, C. P., Nickles, R. J., & Cai, W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509667112 · Cited by 67
Azagury, D. E., Dua, M. M., Barrese, J. C., Henderson, J. M., Buchs, N. C., Ris, F., Cloyd, J. M., Martinie, J. B., Razzaque, S., Nicolau, S., et al. (2015) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2015.10.001 · Cited by 65
Stepanenko, A. A., & Chekhonin, V. P. (2018) · Cancers · doi:10.3390/cancers10120492 · Cited by 65
Fan, C., Wang, T.-W., Hsieh, Y., Wang, C., Gao, Z., Kim, A., Nagasaki, Y., & Yeh, C. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b22468 · Cited by 65
Wang, B., Lv, L., Wang, Z., Jiang, Y., Lv, W., Liu, X., Wang, Z., Zhao, Y., Xin, H., & Xu, Q. (2015) · Scientific Reports · doi:10.1038/srep16589 · Cited by 63
Role of diffusion tensor imaging in brain tumor surgery
Dubey, A., Kataria, R., & Sinha, V. D. (2018) · Asian Journal of Neurosurgery · doi:10.4103/ajns.ajns_226_16 · Cited by 63
Jo, Y., Kim, E. H., Sai, S., Kim, J. S., Cho, J.-M., Kim, H., Baek, J., Kim, J., Hwang, S., & Yoon, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113684 · Cited by 63
Brown, N. F., McBain, C. A., Nash, S., Hopkins, K., Sanghera, P., Saran, F. H., Phillips, M., Dungey, F. A., Clifton‐Hadley, L., Wanek, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156369 · Cited by 62
Schiff, D., Jaeckle, K. A., Anderson, S. K., Galanis, E., Giannini, C., Buckner, J. C., Stella, P. J., Flynn, P. J., Erickson, B. J., Schwerkoske, J. F., et al. (2018) · Cancer · doi:10.1002/cncr.31219 · Cited by 62
Franceschi, E., Stupp, R., van den Bent, M. J., van Herpen, C., Laigle–Donadey, F., Gorlia, T., Hegi, M. E., Lhermitte, B., Strauss, L. C., Allgeier, A., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos256 · Cited by 61
Gajewski, T. F., Sosman, J. A., Gerson, S. L., Liu, L., Dolan, M. E., Lin, S., & Vokes, E. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0060 · Cited by 61
Li, Y., Wu, M., Zhang, N., Tang, C., Jiang, P., Liu, X., Yan, F., & Zheng, H. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13695 · Cited by 61
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Gerstner, E. R., Ye, X., Duda, D. G., Levine, M. A., Mikkelsen, T., Kaley, T. J., Olson, J. J., Nabors, B. L., Ahluwalia, M. S., Wen, P. Y., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov085 · Cited by 60
Oncolytic Virotherapy in Glioma Tumors
Rius‐Rocabert, S., Garcia‐Romero, N., García, A., Ayuso‐Sacido, Á., & Nistal‐Villán, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207604 · Cited by 60
Stereotactic Radiosurgery for Glioblastoma
Redmond, K. J., & Mehta, M. P. (2015) · Cureus · doi:10.7759/cureus.413 · Cited by 58
Correction: Corrigendum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs
Sampaolesi, M., Blot, S., D’Antona, G., Granger, N. P., Tonlorenzi, R., Innocenzi, A., Mognol, P., Thibaud, J. L., Gálvez, B. G., Barthélémy, I., et al. (2013) · Nature · doi:10.1038/nature11976 · Cited by 56
Brent, T. P., & Remack, J. S. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.14.6779 · Cited by 56
Wu, S., Gao, F., Zheng, S., Zhang, C., Martínez-Ledesma, E., Ezhilarasan, R., Ding, J., Li, X., Feng, N., Multani, A. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2549 · Cited by 55
Broniscer, A., Jia, S., Mandrell, B. N., Hamideh, D., Huang, J., Onar‐Thomas, A., Gajjar, A. J., Raimondi, S. C., Tatevossian, R., & Stewart, C. F. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27035 · Cited by 54
Ene, C. I., Kreuser, S. A., Jung, M., Zhang, H., Arora, S., White Moyes, K., Szulzewsky, F., Barber, J., Cimino, P. J., Wirsching, H.-G., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz226 · Cited by 54
Stritzelberger, J., Distel, L. V., Buslei, R., Fietkau, R., & Putz, F. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1743-x · Cited by 53
Hong, T., Li, H., Su, Y., Feng, D., Wang, X., Zhang, C., Ma, H., & Hu, Q. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2077-4 · Cited by 52
Aasland, D., Reich, T. R., Tomicic, M. T., Switzeny, O. J., Kaina, B., & Christmann, M. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14262 · Cited by 51
T lymphocyte-targeted immune checkpoint modulation in glioma
Kelly, W., Giles, A. J., & Gilbert, M. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000379 · Cited by 51
Surgical approaches for the gliomas
Watts, C., & Sanai, N. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00004-9 · Cited by 50
Noonan, E. M., Shah, D., Yaffe, M. B., Lauffenburger, D. A., & Samson, L. D. (2012) · Integrative Biology · doi:10.1039/c2ib20091k · Cited by 49
Lee, C., Kim, G. R., Yoon, J., Kim, S. E., Yoo, J. S., & Piao, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-29424-4 · Cited by 49
Balañá, C., Gil‐Gil, M., Pérez, P., Reynés, G., Gallego, O. S., Ribalta, T., Capellades, J., González‐Ortiz, S., & Verger, E. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0305-1 · Cited by 48
Microfluidics in Malignant Glioma Research and Precision Medicine
Logun, M. T., Zhao, W., Mao, L., & Karumbaiah, L. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700221 · Cited by 48
T-cell exhaustion in glioblastoma
Woroniecka, K. I., & Fecci, P. E. (2018) · Oncotarget · doi:10.18632/oncotarget.26228 · Cited by 48
Jovčevska, I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00798 · Cited by 48
BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53
Nie, E., Jin, X., Wu, W., Yu, T., Zhou, X., Zhi, T., Shi, Z., Zhang, J., Liu, N., & You, Y. (2016) · Scientific Reports · doi:10.1038/srep39743 · Cited by 47
Self-citationA Novel Theranostic Strategy for MMP-14 –Expressing Glioblastomas Impacts Survival
Mohanty, S., Chen, Z., Li, K., Morais, G. R., Klockow, J., Yerneni, K., Pisani, L. J., Chin, F. T., Mitra, S., Cheshier, S. H., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0022 · Cited by 47
Self-citationPatil, R., Galstyan, A., Sun, T., Shatalova, E. S., Butte, P. V., Mamelak, A. N., Carico, C., Kittle, D. S., Grodzinski, Z. B., Chiechi, A., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.029 · Cited by 47
Lee, C. A. A., Banerjee, P., Wilson, B. J., Wu, S., Guo, Q., Berg, G., Karpova, S. A., Mishra, A., Lian, J. W., Tran, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013778 · Cited by 47
Shao, J., Radakovich, N., Grabowski, M. M., Borghei-Razavi, H., Knusel, K. D., Joshi, K. C., Muhsen, B. A., Hwang, L. S., Barnett, G. H., & Mohammadi, A. M. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.03.213 · Cited by 47
MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein
Pradhan, A. K., Maji, S., Das, S. K., Emdad, L., Sarkar, D., & Fisher, P. B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09886-7 · Cited by 47
Tomiyama, A., Tachibana, K., Suzuki, K., Seino, S., Sunayama, J., Matsuda, K.-I., Sato, A., Matsumoto, Y., Nomiya, T., Nemoto, K., et al. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.37 · Cited by 46
Valdez, J. M., Johnstone, A. F. M., Richards, J. H., Schmid, J. E., Royland, J. E., & Kodavanti, P. R. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010011 · Cited by 46
Yang, Z., Wei, D., Dai, X., Stevens, M. F. G., Bradshaw, T. D., Luo, Y., & Zhang, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00485 · Cited by 46
Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells
Wu, W. E., Schecker, J., Würstle, S. M., Schneider, F., Schönfelder, M., & Schlegel, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.036 · Cited by 45
Self-citationCell Cycle Changes after Glioblastoma Stem Cell Irradiation: The Major Role of RAD51
Tachon, G., Cortes, U., Guichet, P., Rivet, P., Balbous, A., Masliantsev, K., Berger, A., Boissonnade, O., Wager, M., & Karayan, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103018 · Cited by 45
Peigñan, L., Garrido, W., Segura, R., Melo, R., Rojas, D., Cárcamo, J. G., Martín, R. S., & Quezada, C. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0464-8 · Cited by 44
Stem Cell Therapies in Retinal Disorders
Shukla, A. G., Yang, J. Y., Lee, W., & Tsang, S. H. (2017) · Cells · doi:10.3390/cells6010004 · Cited by 43
Angiogenesis inhibitors in tackling recurrent glioblastoma
Hundsberger, T., Reardon, D. A., & Wen, P. Y. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1322903 · Cited by 43
Forte, I. M., Indovina, P., Iannuzzi, C. A., Cirillo, D., Marzo, D. D., Barone, D., Capone, F., Pentimalli, F., & Giordano, A. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4788 · Cited by 43
Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
Menotti, L., & Avitabile, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218310 · Cited by 43
Targeting Anti-Apoptotic BCL-2 Family Proteins for Cancer Treatment
Zhang, X., Liu, X., Zhou, D., & Zheng, G. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0004 · Cited by 42
Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3
Komiyama, T., Ogura, A., Hirokawa, T., Zhijing, M., Kamiguchi, H., Asai, S., Miyachi, H., & Kobayashi, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010012 · Cited by 41
The Organoid Era Permits the Development of New Applications to Study Glioblastoma
Andreatta, F., Beccaceci, G., Fortuna, N., Celotti, M., Felice, D. D., Lorenzoni, M., Foletto, V., Genovesi, S., Rubert, J., & Alaimo, A. (2020) · Cancers · doi:10.3390/cancers12113303 · Cited by 40
Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields
Chang, E., Pohling, C., Beygui, N., Patel, C. B., Rosenberg, J., Ha, D. H., & Gambhir, S. S. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2534-5 · Cited by 39
Self-citationNawaz, M. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.10.04 · Cited by 37
Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation
Huang, Y.-C., Lin, S., Shih, H., Chou, C.-H., Chu, H.-H., Chiu, C., Yuh, C., Yeh, T., & Cheng, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18668 · Cited by 36
Hedgehog signaling sensitizes Glioma stem cells to endogenous nano-irradiation
Morgenroth, A., Vogg, A. T. J., Ermert, K., Zlatopolskiy, B. D., & Mottaghy, F. M. (2014) · Oncotarget · doi:10.18632/oncotarget.2123 · Cited by 35
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02
Nghiemphu, P. L., Ebiana, V., Wen, P. Y., Gilbert, M. R., Abrey, L. E., Lieberman, F. S., DeAngelis, L. M., Robins, H. I., Yung, W. K. A., Chang, S. M., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2624-4 · Cited by 33
Sautter, L., Hofheinz, R., Tuettenberg, J., Grimm, M., Vajkoczy, P., Groden, C., Schmieder, K., Hochhaus, A., Wenz, F. K., & Giordano, F. A. (2019) · Oncology · doi:10.1159/000502483 · Cited by 33
Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma
Stark, A. M., Doukas, A., Hugo, H. ‐., Hedderich, J., Hattermann, K., Mehdorn, H. M., & Held‐Feindt, J. (2014) · Neurological Research · doi:10.1179/1743132814y.0000000409 · Cited by 32
Xiu, J., Piccioni, D. E., Juarez, T., Pingle, S. C., Hu, J. L., Rudnick, J. D., Fink, K., Spetzler, D. B., Maney, T., Ghazalpour, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7722 · Cited by 32
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma
Sun, Q., Pei, C., Li, Q., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.093 · Cited by 32
Effects of 5-ALA dose on resection of glioblastoma
Michael, A. P., Watson, V. L., Ryan, D. H., Delfino, K. R., Bekker, S. V., & Cozzens, J. W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03100-7 · Cited by 32
Kong, L., Wu, J., Gao, J., Qiu, X., Yang, J., Hu, J., Hu, W., Mao, Y. Q., & Lu, J. J. (2020) · Cancer · doi:10.1002/cncr.32828 · Cited by 32
Erlotinib: early clinical development in brain cancer
Addeo, R., Zappavigna, S., Parlato, C., & Caraglia, M. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918950 · Cited by 31
Machine learning approaches to study glioblastoma: A review of the last decade of applications
Valdebenito, J., & Medina, F. (2019) · Cancer Reports · doi:10.1002/cnr2.1226 · Cited by 31
Cited by
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Glioblastoma modeling with 3D organoids: progress and challenges
Wang, X., Sun, Y., Zhang, D. Y., Ming, G.-L., & Song, H. (2023) · Oxford Open Neuroscience · doi:10.1093/oons/kvad008 · Cited by 46
“Treatment resistance and recurrence of GBM are mainly driven by several characteristics including, but not limited to, diffuse infiltration of brain parenchyma, rapid proliferation, high intertumoral and intratumoral heterogeneity and an immune-cold tumor microenvironment [4].”
BackgroundSarli, S. L., Fakih, H. H., Kelly, K., Devi, G., Rembetsy-Brown, J. M., McEachern, H. R., Ferguson, C. M., Echeverria, D., Lee, J., Sousa, J., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae260 · Cited by 18
Metadata
- Authors
- Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 171
- Pages
- 105780
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W3185482622
- Cited by
- 805
- References
- 427
- FWCI
- 43.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.